ABERNETHY MATT

CIK 00017240972 companiesSAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001724097

Recent Transactions

50 trades

Award
FATE THERAPEUTICS INC$FATE
Stock Option (Right to Buy)
2026-06-12+87,900→ 87,900 total
Gift
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-03-04−2,249→ 42,808 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-13+2,241→ 40,320 total
Tax Payment
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-13$124.12/sh−1,210→ 39,110 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-13+2,566→ 41,676 total
Tax Payment
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-13$124.12/sh−1,385→ 40,291 total
Award
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-13+9,968→ 50,259 total
Tax Payment
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-13$124.12/sh−5,378→ 44,881 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2026-02-13−2,241→ 4,484 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2026-02-13−2,566→ 2,566 total
Award
NEUROCRINE BIOSCIENCES INC$NBIX
Stock Option
2026-02-13+44,095→ 44,095 total
Award
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2026-02-13+7,735→ 7,735 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-12+2,133→ 39,230 total
Tax Payment
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-02-12$123.10/sh−1,151→ 38,079 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2026-02-12−2,133→ 6,401 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-01-31+2,437→ 38,465 total
Tax Payment
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2026-01-31$136.06/sh−1,368→ 37,097 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2026-01-31−2,437→ 0 total
Award
FATE THERAPEUTICS INC$FATE
Stock Option (Right to Buy)
2025-05-29+110,000→ 110,000 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-02-13$116.85/sh−1,352→ 34,775 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-02-13$116.87/sh−1,206→ 35,810 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-02-13+2,566→ 36,127 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2025-02-13−2,566→ 5,132 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-02-13+2,241→ 37,016 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2025-02-13−2,241→ 6,725 total
Award
NEUROCRINE BIOSCIENCES INC$NBIX
Stock Option
2025-02-12+45,538→ 45,538 total
Award
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2025-02-12+8,534→ 8,534 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-02-10$118.27/sh−980→ 33,561 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-02-08+1,860→ 34,541 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2025-02-08−1,860→ 0 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-01-31+2,436→ 33,964 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2025-01-31$152.87/sh−1,283→ 32,681 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2025-01-31−2,436→ 2,437 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Non-Qualified Stock Option
2024-08-13−14,100→ 0 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-08-13$73.60/sh+14,100→ 45,628 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-08-13$150.38/sh−14,100→ 31,528 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-07-16$73.60/sh+900→ 32,428 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-07-16$150.04/sh−900→ 31,528 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Non-Qualified Stock Option
2024-07-16−900→ 14,100 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-05-15$140.24/sh−15,000→ 31,528 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-05-15$73.60/sh+15,000→ 46,528 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Non-Qualified Stock Option
2024-05-15$73.60/sh−15,000→ 15,000 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-05-14$135.66/sh−15,000→ 31,528 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-05-14$73.60/sh+15,000→ 46,528 total
Exercise/Conversion
NEUROCRINE BIOSCIENCES INC$NBIX
Non-Qualified Stock Option
2024-05-14$73.60/sh−15,000→ 30,000 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-02-13$132.85/sh−1,352→ 31,528 total
Award
NEUROCRINE BIOSCIENCES INC$NBIX
Stock Option
2024-02-13+45,058→ 45,058 total
Award
NEUROCRINE BIOSCIENCES INC$NBIX
Restricted Stock Unit
2024-02-13+8,966→ 8,966 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-02-08$134.21/sh−980→ 30,314 total
Sale
NEUROCRINE BIOSCIENCES INC$NBIX
Common Stock
2024-02-06$142.19/sh−1,280→ 29,434 total

Companies

Recent Filings

Address

C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE

SAN DIEGO, CA, 92131

View on SEC.gov